Emerging Biomarkers Have Potential to Refine Patient Selection, Improve Immunotherapy Strategies
+more
Drs. Marina Chiara Garassino, Sulin Wu, and Faith Abodunrin offer insights from the RELATIVITY-104 and GALAXIES Lung-201 Trials. Read more
During the opening plenary session at the 2024 Asia Conference on Lung Cancer, experts offered their perspectives on clinical trials, combination therapies, and research initiatives. Read more
Promising results from the phase III IMforte trial reveal a potential first-line therapy for patients with ES-SCLC. Read more
Prof. Glenwood Goss said adjuvant durvalumab did not improve disease-free survival outcomes following complete resection and optional chemotherapy. Read more
Dr. Mike Gieske said since implementing a multidisciplinary screening approach, his healthcare system has seen a 19% decrease in late-stage lung cancers, and they now see more early-stage than late-stage lung cancers. Read more
Nine difference-makers in the field of lung cancer shared their groundbreaking work during the IASLC Lectureship Awards presentations at WCLC 2024. Read more
Prof. Benjamin Besse said the TKI showed encouraging clinical activity in patients who were heavily pre-treated. Read more
Dr. Alexander Drilon said most patients with ALK-positive NSCLC treated with NVL-655 showed disease regression and deep responses. Read more
Dr. Matt Warkentin says in those without significant comorbidity and who are fit for surgery, screening may provide survival benefits. Read more